InSite, Senju deal

InSite granted Senju an exclusive, Japanese license to develop and commercialize InSite's azithromycin

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE